Identification of Coinfections by Viral and Bacterial Pathogens in COVID-19 Hospitalized Patients in Peru: Molecular Diagnosis and Clinical Characteristics.
Giancarlo Pérez-LazoWilmer Silva-CasoJuana Del Valle-MendozaAdriana Morales-MorenoJosé Ballena-LópezFernando Soto-FebresJohanna Martins-LunaHugo Carrillo-NgLuis Javier Del ValleSungmin KymMiguel Angel Aguilar-LuisIssac Peña-TuestaCarmen Tinco-ValdezLuis Ricardo IllescasPublished in: Antibiotics (Basel, Switzerland) (2021)
The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.
Keyphrases
- respiratory tract
- end stage renal disease
- sars cov
- ejection fraction
- coronavirus disease
- chronic kidney disease
- newly diagnosed
- healthcare
- public health
- emergency department
- prognostic factors
- mental health
- physical activity
- acute kidney injury
- peritoneal dialysis
- risk assessment
- high intensity
- gram negative
- early onset
- gene therapy
- climate change
- antimicrobial resistance
- single molecule
- acute respiratory distress syndrome
- middle aged